Business Wire

LFB-SA

Share
2015, a Strategic Year for LFB

Key events in 2015 :

  • Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
  • Two new products registered in Europe
  • Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
  • Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
  • Turnover of €502.4 million, stable in comparison to 2014

Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In 2015, the key milestones have been successfully achieved. It has been a historic and productive year for the future of LFB."

An unprecedented increase in capital in order to finance the group's development
As part of the group's strategic development, LFB's shareholder (the French State) decided in October to underwrite an increase in LFB's share capital by €230 million. The share capital of the company now stands at €280 million. To meet the financing needs of LFB's development project, on 5 January 2016 LFB issued a senior bond of €124 million. These funds will enable the construction of a 'new generation' plant in Arras. This flagship project, representing an investment of approximately €300 million, will enable LFB to triple its global production capacity in 2020 with facilities aimed at manufacturing for the whole world.
LFB is also developing its sites in Alès (Gard) and Charlton (USA), establishing bio-production facilities for recombinant medicines in development.

Consolidated earnings in €M

  2015   2014   Variation 2015/2014

Turnover

 

502.4

 

501.9

 

0.1 %

Gross margin

 

177.6

 

195.5

 

-9.2 %

Research & development

 

(81.3)

 

(65.9)

   

Commercial costs

 

(51.0)

 

(48.6)

 

General costs

 

(50.3)

 

(48.7)

 

Other charges and
operational income

 

17.0

 

(7.1)

 

Operational earnings

 

12.0

 

25.2

 

as a % of turnover

 

2.4 %

 

5.0 %

 

Net earnings

 

0.3

  13  

€90.5 million* before research tax credit

2015 turnover - growth in international sales
At €502.4 million, turnover is relatively stable as compared to 2014. For the second successive year, the group's turnover exceeded €500 million, with the international side business continuing to grow. Despite a 3.2 % decline in turnover in France during 2015, international sales rose by €12.1 million (+8.7%), reaching €152 million. This figure represents 30% of consolidated turnover (28% in 2014).

Operational earnings decline in order to finance strategy
Research and development costs are increasing rapidly (€81.3 million), owing to the large number of phase III trials in progress. Various strategic projects reached significant milestones. In 2015, two new LFB products, a 10% immunoglobulin and a fibrinogen have been subject to a mutual recognition in procedure in Europe with the Paul Ehrlich Institute as the referral agency. Two other recombinant products are currently at the end of phase III. At the same time, LFB is planning to manufacture product batches for launch, which has had an impact on earnings. In 2015, the group posted encouraging operational income (€17 million), notably owing to its holding in the bio-tech company TG Therapeutics Inc. The positive operational earnings (€12.0 million) is down as compared to that of 2014 (-13.2 million) due to a decline in gross margins and increased development costs. Despite this unprecedented effort, net earnings remain positive at €0.3 million.

About LFB Group
LFB is a bio-pharmaceutical company that develops, manufactures, and markets medicinal products from living systems for the treatment of serious and often rare diseases in the fields of Immunology, Hemostasis, Perinatal, and Intensive Care. Currently ranked 6th worldwide in the field of plasma-derived medicinal products, LFB Group is also among the leading European companies in the development and production of proteins and innovative treatments derived from bio-technologies. It employs 2,111 staff worldwide.
http://www.groupe-lfb.fr

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact:

LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication Director
charrieres@lfb.fr
or
David Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release

HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e

Wizz Air Tops Major Airline Emissions Rankings2.7.2025 11:00:00 CEST | Press release

Cirium, the aviation analytics company, creates a new transparent standard and ranking for airline CO2 emissions, identifying the best performing airlines in specific categories Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments.

L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 10:59:00 CEST | Press release

Multi-year collaboration in LTTS’ Mobility segment to drive platform synergies, electrification, and innovation for TRATON GROUP L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration position

Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 10:30:00 CEST | Press release

Named Official Digital Wealth Platform of the DP World Tour through 2027 Nexo becomes Title Partner of the Nexo Championship, which takes place at Trump International Golf Links in August 2025 Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Champion

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 10:00:00 CEST | Press release

Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (follitropin delta); alongside its existing unique algorithm-based dosing Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 wome

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye